PGIMER, Chandigarh, India.
Sir Ganga Ram Hospital, India.
J Vasc Access. 2022 Nov;23(6):849-860. doi: 10.1177/11297298211011375. Epub 2021 May 3.
South and Southeast Asia is the most populated, heterogeneous part of the world. The Association of Vascular Access and InTerventionAl Renal physicians (AVATAR Foundation), India, gathered trends on epidemiology and Interventional Nephrology (IN) for this region. The countries were divided as upper-middle- and higher-income countries as Group-1 and lower and lower-middle-income countries as Group-2. Forty-three percent and 70% patients in the Group 1 and 2 countries had unplanned hemodialysis (HD) initiation. Among the incident HD patients, the dominant Vascular Access (VA) was non-tunneled central catheter (non-TCC) in 70% of Group 2 and tunneled central catheter (TCC) in 32.5% in Group 1 countries. Arterio-Venous Fistula (AVF) in the incident HD patients was observed in 24.5% and 35% of patients in Group-2 and Group-1, respectively. Eight percent and 68.7% of the prevalent HD patients in Group-2 and Group-1 received HD through an AVF respectively. Nephrologists performing any IN procedure were 90% and 60% in Group-2 and Group 1, respectively. The common procedures performed by nephrologists include renal biopsy (93.3%), peritoneal dialysis (PD) catheter insertion (80%), TCC (66.7%) and non-TCC (100%). Constraints for IN include lack of time (73.3%), lack of back-up (40%), lack of training (73.3%), economic issues (33.3%), medico-legal problems (46.6%), no incentive (20%), other interests (46.6%) and institution not supportive (26%). Routine VA surveillance is performed in 12.5% and 83.3% of Group-2 and Group-1, respectively. To conclude, non-TCC and TCC are the most common vascular access in incident HD patients in Group-2 and Group-1, respectively. Lack of training, back-up support and economic constraints were main constraints for IN growth in Group-2 countries.
南亚和东南亚是世界上人口最多、最多样化的地区。印度的血管通路和介入肾脏病协会(AVATAR 基金会)收集了该地区的流行病学和介入肾脏病学趋势。这些国家被分为中上收入和高收入国家(第 1 组)和低收入和中下收入国家(第 2 组)。第 1 组和第 2 组国家中,43%和 70%的血液透析(HD)患者为非计划性开始 HD。在新发生的 HD 患者中,第 2 组国家 70%的主要血管通路(VA)为非隧道中央导管(非 TCC),第 1 组国家 32.5%为隧道中央导管(TCC)。新发生的 HD 患者中,动静脉瘘(AVF)分别占第 2 组和第 1 组患者的 24.5%和 35%。第 2 组和第 1 组中分别有 8%和 68.7%的现患 HD 患者通过 AVF 接受 HD。在第 2 组和第 1 组中,分别有 90%和 60%的肾脏病学家进行任何介入治疗。肾脏病学家进行的常见操作包括肾活检(93.3%)、腹膜透析(PD)导管插入术(80%)、TCC(66.7%)和非 TCC(100%)。介入治疗的限制因素包括缺乏时间(73.3%)、缺乏后备支持(40%)、缺乏培训(73.3%)、经济问题(33.3%)、医学法律问题(46.6%)、无激励措施(20%)、其他利益(46.6%)和机构不支持(26%)。第 2 组和第 1 组分别有 12.5%和 83.3%的患者常规进行 VA 监测。结论:在第 2 组和第 1 组的新发生 HD 患者中,非 TCC 和 TCC 是最常见的血管通路。缺乏培训、后备支持和经济限制是第 2 组国家介入治疗发展的主要限制因素。